Consumer Healthcare Products Australia (CHP Australia) welcomes the Therapeutic Goods Administration’s (TGA) consultation on proposed additional controls for certain sunscreen ingredients.

CHP Australia and its members are proud to be aligned with the regulator in providing Australians with some of the best sun protection products available globally. Regular reviews of emerging scientific evidence to ensure sunscreen ingredients meet the highest standards of safety for repeated, long-term use are an important part of maintaining public confidence and align with our commitment to putting consumers first.

As part of the consultation, the TGA is seeking feedback on proposed additional safeguards for two active ingredients—homosalate and oxybenzone—and one degradant, benzophenone—based on a precautionary assessment of the current literature and exposure modelling. Importantly, the TGA is not proposing any warnings, bans or product recalls, and Australians can remain confident in the safety and effectiveness of locally approved sunscreens.

Australia has one of the highest rates of skin cancer in the world. It is vital that Australians remain vigilant about all forms of sun protection. CHP Australia supports the TGA’s reminder that sunscreens, when used as directed on the label and in combination with other protective measures—such as wearing sun-protective clothing, a broad-brimmed hat and sunglasses, and seeking shade—play a key role in preventing sunburn and reducing the risk of skin cancer.

CHP Australia looks forward to working closely with the TGA, industry stakeholders and consumers to ensure Australians continue to have access to world-leading sun protection supported by robust scientific and regulatory frameworks.